The effect of various forms of folates on cognitive functions in patients with chronic schizophrenia

Zhilyaeva T.V.

Privolzhsky Research Medical University

Blagonravova A.S.

Privolzhsky Research Medical University

Mazo G.E.

Bekhterev National Medical Research Center for Psychiatry and Neurology

ORCID: 0000-0001-7910-9129

The effect of various forms of folates on cognitive functions in patients with chronic schizophrenia

Authors:

Zhilyaeva T.V., Blagonravova A.S., Mazo G.E.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(9): 87‑92

DOI: 10.17116/jnevro202012009187

Downloaded: 94

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Zhilyaeva TV, Blagonravova AS, Mazo GE. The effect of various forms of folates on cognitive functions in patients with chronic schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(9):87‑92. (In Russ.)
https://doi.org/10.17116/jnevro202012009187

Close metadata

OBJECTIVE

To assess the dynamics of cognitive functions in patients with schizophrenia during intake of various forms of folate as an add-on to antipsychotic therapy.

MATERIAL AND METHODS

Using a battery of cognitive tests, the authors evaluated the dynamics of cognitive functions in 3 groups of patients with schizophrenia who received folic acid (n=25), metafolin (n=25) during 4 weeks and in the control group (n=25). Genetic variants of the polymorphism of the folate metabolism enzyme methylenetetrahydrofolate reductase (MTHFR) 677C>T were determined using real-time PCR. Only the carriers of the minor T allele were included in the study.

RESULTS AND CONCLUSION

The improvement of certain cognitive functions was noted after folate administration, it was more pronounced and statistically significant in the metapholin group. The results hold promises for further studies of prolonged use of folate in prophylactic doses for schizophrenia.

Keywords:

folates

schizophrenia

single nucleotide polymorphism MTHFR 677 C>T

cognitive impairment

Authors:

Zhilyaeva T.V.

Privolzhsky Research Medical University

Blagonravova A.S.

Privolzhsky Research Medical University

Mazo G.E.

Bekhterev National Medical Research Center for Psychiatry and Neurology

ORCID: 0000-0001-7910-9129

Received:

21.01.2020

Accepted:

08.04.2020

List of references:

Sommer I, Begemann M, Temmerman A, Leucht S. Pharmacological Augmentation Strategies for Schizophrenia Patients With Insufficient Response to Clozapine: A Quantitative Literature Review. Schizophr Bull. 2011;38(5):1003-1011. https://doi.org/10.1093/schbul/sbr004
Bottiglieri T, Hyland K, Laundy M, Godfrey P, Carney MWP, Toone BK, Reynolds EH. Enhancement of recovery from psychiatric illness by methylfolate. The Lancet. 1990;336(8730-8731):1579-1580. https://doi.org/10.1016/0140-6736(90)93355-S
Levine J, Stahl Z, Sela B, Ruderman V, Shumaico O, Babushkin I, Osher Y, Bersudsky Y, Belmaker RH. Homocysteine-Reducing Strategies Improve Symptoms in Chronic Schizophrenic Patients with Hyperhomocysteinemia. Biol Psychiatry. 2006;60(3):265-269. https://doi.org/10.1016/j.biopsych.2005.10.009
Hill M, Shannahan K, Jasinski S, Macklin EA, Raeke L, Roffman JL, Goff DC. Folate supplementation in schizophrenia: A possible role for MTHFR genotype. Schizophr Res. 2011;127(1-3):41-45. https://doi.org/10.1016/j.schres.2010.12.006
Roffman J, Lamberti J, Achtyes E, Macklin EA, Galendez GC, Raeke LH, Silverstein NJ, Smoller JW, Hill M, Goff DC. Randomized Multicenter Investigation of Folate Plus Vitamin B12 Supplementation in Schizophrenia. JAMA Psychiatry. 2013;70(5):481. https://doi.org/10.1001/jamapsychiatry.2013.900
Brown H, Roffman J. Vitamin Supplementation in the Treatment of Schizophrenia. CNS Drugs. 2014;28(7):611-622. https://doi.org/10.1007/s40263-014-0172-4
Pustotina OA. Achievements and risks of folate use during and not in pregnancy. Meditsinskii Sovet. 2015;9:92-99. (In Russ.).
Roffman J, Petruzzi L, Tanner A, Brown HE, Eryilmaz H, Ho NF, Giegold M, Silverstein NJ, Bottiglieri T, Manoach DS, Smoller JW, Henderson DC, Goff DC. Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial. Mol Psychiatry. 2017;23(2):316-322. https://doi.org/10.1038/mp.2017.41
Choi J, Yates Z, Veysey M, Heo Y, Lucock M. Contemporary Issues Surrounding Folic Acid Fortification Initiatives. Prev Nutr Food Sci. 2014;19(4):247-260. https://doi.org/10.3746/pnf.2014.19.4.247
Roffman J, Weiss A, Deckersbach T., Freudenreich O, Henderson DC, Purcell S, Wong DH, Halsted CH, Goff DC. Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia. Schizophr Res. 2007;92(1-3):181-188. https://doi.org/10.1016/j.schres.2007.01.003

Close metadata